The Hidden Risk Behind a Healthcare Dividend Favorite

48-year dividend growth streak, 3.2% yield, and a diabetes spin-off – Medtronic (MDT) is the quiet dividend powerhouse you’ve been sleeping on

MaxDividends Mission: Helping people build growing passive income, retire early, and live off dividends.

For dividend investors seeking opportunities with strong growth potential, MaxDividends Stock Ideas offers a daily, in-depth look at companies worth considering for a dividend portfolio.

---

---

Intro

💡 Invest in companies you believe in - W. Buffett

If you're looking for stocks that have delivered growing dividends for decades, Medtronic (NYSE: MDT) should be at the top of your watchlist.

The medical technology leader is already part of the elite Dividend Aristocrats club and is now just 2 years away from achieving Dividend King status—requiring only two more annual payout increases to cement its place among the most reliable income stocks.

With a current dividend yield of ~3.1% (above the S&P 500 average) and analysts forecasting 28% upside potential in the coming years, MDT presents a compelling mix of income and growth.

But Medtronic isn’t just a dividend story. The company is undergoing a major strategic restructuring, spinning off its diabetes division to sharpen its focus on high-margin segments: cardiovascular, neuroscience, and surgical innovations.

Scroll to read — if no access, check your plan and upgrade

---

---

So, is now the time to buy Medtronic while the market still undervalues its potential? Let’s dive in.